Skip to content
ACT · Science

Gene editing

Gene editing appears in 5 reviewed ACT questions and sits in Science. Below are worked examples showing exactly how the exam tests it, with the answer marked and every distractor explained.

How Gene editing is tested

Example 1Medium
Scientist 1: CRISPR-Cas9 gene editing in human embryos should be permitted for therapeutic purposes. CRISPR can precisely correct disease-causing mutations such as those responsible for sickle cell disease or cystic fibrosis before they are passed on. Off-target editing rates have fallen below 0.1% with current high-fidelity Cas9 variants, making the technology sufficiently safe for clinical use. The potential to eliminate heritable diseases outweighs residual technical risks. Scientist 2: CRISPR editing of human embryos should remain prohibited. Germline edits are heritable by all future descendants, making any error permanent across generations. Even low off-target rates are unacceptable when multiplied across billions of cells and countless descendants. Furthermore, the boundary between therapeutic editing and enhancement is difficult to enforce, raising the prospect of designer babies. A moratorium is needed until long-term safety data exist. Both scientists would most likely agree with which statement?
  1. AOff-target editing rates are too high to consider CRISPR safe for any application.
  2. BCRISPR-Cas9 editing of human embryos should be approved for clinical use immediately.
  3. CCRISPR-Cas9 technology can make targeted changes to specific DNA sequences.Correct
  4. DGermline edits pose no greater heritable risk than somatic cell edits.

Why C is right

Both scientists accept that CRISPR-Cas9 can make targeted DNA edits — Scientist 1 cites its precision as an argument for use, and Scientist 2 acknowledges its power as a reason for caution. Neither disputes the basic technical capability of the tool. They disagree on safety sufficiency, permissibility, and ethical boundaries.
Why the other 3 choices miss
A
Incorrect because Scientist 1 argues off-target rates are now below 0.1%, which they consider sufficiently safe.
B
Incorrect because Scientist 2 explicitly opposes immediate clinical approval and calls for a moratorium.
D
Incorrect because Scientist 2 specifically emphasizes that germline edits are heritable and therefore riskier than somatic edits.
Example 2Easier
Scientists are testing CRISPR-Cas9 gene editing efficiency on four bacterial strains by attempting to introduce a specific gene sequence. The results after 48 hours are shown below: Bacterial Strain | Guide RNA Match (%) | Editing Efficiency (% of cells edited) Strain A | 100 | 87 Strain B | 95 | 61 Strain C | 85 | 28 Strain D | 75 | 9 Based on the data, which of the following is the most reasonable conclusion?
  1. ABacterial strains with lower guide RNA matches produce more edited cells overall.
  2. BCRISPR editing is only effective when guide RNA match is exactly 100%.
  3. CCRISPR editing efficiency is independent of guide RNA match percentage.
  4. DHigher guide RNA match percentage is positively correlated with higher editing efficiency.Correct

Why D is right

Read the table from lowest to highest guide RNA match. At 75% match, 9% of cells are edited. At 85%, it is 28%; at 95%, it is 61%; and at 100%, it is 87%. Editing efficiency rises every time the match percentage rises, so the two variables are positively correlated, which is choice D.
Why the other 3 choices miss
A
This reverses the trend. Strain D has the lowest match (75%) and the fewest edited cells (9%), while Strain A has the highest match (100%) and the most (87%).
B
This overstates the data. Editing still works below 100% match: Strain B (95%) had 61% of cells edited, and even Strain D (75%) had 9%.
C
If efficiency were independent of match, it would stay roughly constant. Instead it climbs steadily from 9% to 87% as the match rises from 75% to 100%.
Example 3Medium
Researchers are testing a new CRISPR delivery method using different viral vectors. Table 1 shows cell viability and editing efficiency after treatment: Vector Type | Cell Viability (%) | Editing Efficiency (%) Adenovirus | 92 | 45 Lentivirus | 78 | 81 Adeno-associated virus (AAV) | 95 | 62 Lipid nanoparticle | 88 | 55 A researcher claims that lentivirus is the best delivery method because it has the highest editing efficiency. What is the most significant weakness of this claim based on the data?
  1. AAdenovirus has a higher editing efficiency than lentivirus.
  2. BLentivirus has the lowest cell viability, meaning many cells die during the editing process.Correct
  3. CLipid nanoparticles cost more than lentiviral vectors.
  4. DAAV has a higher cell viability but a lower editing efficiency than lentivirus.

Why B is right

The claim judges the vectors on editing efficiency alone, where lentivirus does lead (81% vs. 62% for AAV, 55% for lipid nanoparticles and 45% for adenovirus). But Table 1 also shows that lentivirus has the lowest cell viability of the four: 78%, compared with 88-95% for the others. So about 22% of treated cells die, a much higher loss than with any other vector. Calling lentivirus the "best" method ignores this trade-off, which is the claim's most significant weakness (B).
Why the other 3 choices miss
A
This choice misreads the table. Adenovirus has the lowest editing efficiency (45%), well below lentivirus (81%), so the statement is false.
C
Table 1 gives no cost data, so this claim can't be judged from the data. Lipid nanoparticles aren't part of the researcher's claim either.
D
This statement is accurate (95% vs. 78% viability, 62% vs. 81% efficiency), but it only compares one other vector. The bigger weakness is that lentivirus has the lowest viability of all four vectors, which B states directly.

Studied alongside

Other concepts from Science.